Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

288.12 -3.48 (-1.19%)
Streaming Delayed Price Updated: 1:42 PM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 437,869
Open 291.62
Bid (Size) 287.83 (4)
Ask (Size) 288.41 (2)
Prev. Close 291.60
Today's Range 286.22 - 293.47
52wk Range 187.16 - 311.88
Shares Outstanding 147,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023
For those seeking the best discounts in the tech-centered index, these are the most undervalued Nasdaq stocks to buy. 
Via InvestorPlace

Performance

YTD
+5.68%
+5.68%
1 Month
+5.68%
+5.68%
3 Month
+3.50%
+3.50%
6 Month
+34.89%
+34.89%
1 Year
+25.61%
+25.61%

More News

Read More
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
Via InvestorPlace
Is Biogen Stock a Buy Now?
Via The Motley Fool
Where Biogen Stands With Analysts
Via Benzinga
FDA Rejects Eli Lilly's Donanemab For Alzheimer's Disease, Needs More Data
Via Benzinga
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Via MarketBeat
Exposures Product Safety
Lecanemab Receives Priority Review Status in Japan
From Biogen Inc.
Via Globe NewsWire
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
From Biogen Inc.
Via Globe NewsWire
$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?
Via The Motley Fool
In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug
Via Investor's Business Daily
Tech Stocks Get Netflix Boost Amid Jittery Wider Market On Friday, Dow Stares At 4th Straight Loss
Via Benzinga
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
Via The Motley Fool
If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today
Via The Motley Fool
Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen
Via Benzinga
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich
Via The Motley Fool
Elliott Wave Technical Analysis: Biogen Inc.
Via Talk Markets
1 Hot Growth Stock to Buy Now, and 1 to Avoid
Via The Motley Fool
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
Via Talk Markets
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?
Via The Motley Fool
Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill
Via Benzinga
Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug
Via Benzinga
SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.